|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Loans held for investment | |||||||||||||||||||
| Loans held for investment - related party (Note 8) | |||||||||||||||||||
| Loans held for investment, at carrying value | |||||||||||||||||||
| Current expected credit loss reserve | |||||||||||||||||||
| Loans held for investment at carrying value, net | |||||||||||||||||||
| Loans held for sale - related party, at fair value (Note 8) | |||||||||||||||||||
| Loans, at fair value - related party | |||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||
| Interest receivable | |||||||||||||||||||
| Other receivables and assets, net | |||||||||||||||||||
| Related party receivables | |||||||||||||||||||
| Related Party | |||||||||||||||||||
| Total related party receivables | |||||||||||||||||||
| Debt securities, at fair value | |||||||||||||||||||
| Total Assets | |||||||||||||||||||
| Liabilities | |||||||||||||||||||
| Revolving loan | |||||||||||||||||||
| Notes payable, net | |||||||||||||||||||
| Dividend payable | |||||||||||||||||||
| Related party payables | |||||||||||||||||||
| Related Party | |||||||||||||||||||
| Total related party payables | |||||||||||||||||||
| Management and incentive fees payable | |||||||||||||||||||
| Interest payable | |||||||||||||||||||
| Payable for investment purchased | |||||||||||||||||||
| Accounts payable and other liabilities | |||||||||||||||||||
| Interest reserve | |||||||||||||||||||
| Total Liabilities | |||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||
| Common stock, par value $0.01 per share, 100,000,000 shares authorized and 21,314,392 and 21,080,272 shares issued and outstanding, respectively | |||||||||||||||||||
| Additional paid-in-capital | |||||||||||||||||||
| Accumulated deficit | |||||||||||||||||||
| Total stockholders’ equity | |||||||||||||||||||
| Total liabilities and stockholders’ equity | |||||||||||||||||||
Loading...
